Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPAF-CL1151
- Development stage
- Preclinical
- Lead developer
- University of North Carolina at Chapel Hill
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intradermal, Intramuscular, Intranasal
01
Overview
CPAF-CL1151 is a preclinical subunit vaccine candidate being developed for the prevention of Chlamydia trachomatis infections. It consists of the immunodominant, conserved Chlamydial Protease-like Activity Factor (CPAF) antigen covalently conjugated via click-chemistry to CL1151, a potent Stimulator of Interferon Genes (STING) pathway agonist. The vaccine is designed to elicit robust, protective Th1-polarized CD4+ T-cell and humoral immune responses, which are critical for clearing Chlamydia infections and preventing upper genital tract pathology such as hydrosalpinx and infertility. CPAF-CL1151 is being developed through a collaborative partnership between the University of North Carolina at Chapel Hill (UNC Chapel Hill) and Vaxcyte, with funding from the National Institute of Allergy and Infectious Diseases (NIAID).
- Other names
- chlamydial protease-like activity factor-CL1151 conjugateCPAF-CL1151 conjugateCPAF-CL-1151 conjugateCPAF-CL 1151 conjugateCPAF-CL1151 conjugate vaccineCPAF-CL-1151 conjugate vaccineCPAF-CL 1151 conjugate vaccine
02
Targets
IRF3 (Interferon regulatory factor 3)NF-κBSTING (Stimulator of interferon genes protein)γδ TCR (T-cell receptor)TBK1 (TANK binding kinase 1)
Beyond the preview
Go deeper on CPAF-CL1151.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPAF-CL1151.